Aridis Pharmaceuticals Inc. (ARDS) News

Aridis Pharmaceuticals Inc. (ARDS): $1.17

-0.06 (-4.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ARDS News Items

ARDS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ARDS News From Around the Web

Below are the latest news stories about Aridis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning!

William White on InvestorPlace | March 29, 2022

Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aridis Pharmaceuticals (ARDS – Research Report), with a price target of $19.00. The company's shares closed last Thursday at $2.80. According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.1% and a 36.1% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Citius Pharmaceuticals, and Achieve Life Sciences. Aridis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $16.67.

Catie Powers on TipRanks | February 17, 2022

Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study

Aridis Pharmaceuticals Inc''s (NASDAQ: ARDS ) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant . Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, … Full story available on Benzinga.com

Benzinga | February 17, 2022

Aridis, Rhythm top healthcare gainers; 10x Genomics, iSpecimen lead losers pack

Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. 10x Genomics (TXG) -16%. iSpecimen ISPC -10%.

Seeking Alpha | February 17, 2022

Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that both of its fully human monoclonal antibodies (mAbs) in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant. Moreover, both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration.

Yahoo | February 17, 2022

Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop

As far as short squeeze stocks go, these five companies top the list in terms of both short interest and borrow fee rates right now.

Chris MacDonald on InvestorPlace | February 14, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 27, 2022

Aridis Shares Rise On Funding For Inhaled Monoclonal Antibodies Against Influenza, COVID-19

The Bill & Melinda Gates Foundation has granted $1.9 million to Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) to evaluate Aridis'' inhaled monoclonal antibodies (mAbs) against influenza and COVID-19 for low- and middle-income countries. The mAbs will be manufactured using a spirulina-based platform technology developed by Lumen Bioscience. Lumen Bio''s platform can produce therapeutic proteins at lower costs than conventional Full story available on Benzinga.com

Benzinga | January 27, 2022

Aridis, Galapagos lead healthcare gainers; Epizyme, Cue Biopharma among losers

Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.

Seeking Alpha | January 27, 2022

Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, received a grant award from the Bill & Melinda Gates Foundation ('Gates Foundation') to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2 to people in low- and middle-income countries.

Yahoo | January 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5402 seconds.